医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Extension and Advancement of a Peptide Discovery Program

2014年10月03日 PM04:28
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that one of the discovery programs initiated under the strategic alliance with Swiss-based Novartis has advanced into further optimization efforts, and will be extended and funded through an amendment to the original Strategic Alliance Agreement. PeptiDream identified macrocylic peptide candidates against an undisclosed target under the Macrocylic Peptide Drug Discovery Alliance, initiated in 2010 and extended in 2012. Candidates are undergoing optimization efforts in collaboration with Novartis, with PeptiDream using its PDPS system. The amendment provides additional research funding to cover additional PeptiDream resources focusing on the program’s optimization efforts and advancement.

[Comments from Patrick Reid, CSO, and Keiichi Masuya, COO, of PeptiDream Inc.]
“We are very excited with the program’s advancement. The additional funding will allow us to commit more resources toward the optimization efforts of this exciting program.”

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高